These considerations imply that KIF11 inhibitors may represent a promising strategy to be used as adjuvant therapy in breast cancer treatment regimen and may improve TNBC patients’ outcomes showing considerably fewer side effects. This evidence concerns the gene KIF11 and breast carcinoma.